The Brand Name PEGASTA Has Generic Salt :: FILGRASTIM 

PEGASTA  Is From Company INTAS BIO. Priced :: Rs. 13000

PEGASTA have FILGRASTIM is comes under Sub class #N/A of  Main Class #N/A

Main Medicine Class:: #N/A  Sub Medicine Class :: #N/A 

Indications for Drugs ::

Myelosuppressive chemotherapy, Acute Myeloid Leukemia receiving induction or consolidation chemotherapy, Peripheral blood progenitor cell collection and therapy, Severe Neutropenia, Bone marrow transplantation, HIV infection.

Drug Dose ::

Cancer patients receiving myelosuppressive chemotherapy: The recommended starting dose of Filgrastim is 5 mcg/kg/day. Doses may be increased in increments of 5 mcg/kg for each chemotherapy cycle. Cancer patients receiving bone marrow transplant: The recommended dose of Filgrastim following bone marrow transplantation is 10 mcg/kg/day. During the period of neutrophil recovery, the daily dose should be titrated against the neutrophil response as follows: Absolute Neutrophil Count (ANC): Dose adjustment ANC>1000/mm3 for consecutive 3 days Reduces to 5 mcg/kg/day. Then, If ANC remains >1000/mm3 for consecutive 3 days Discontinue drug. Then, If ANC remains <1000/mm3 for consecutive 3 days Resume at 5 mcg/kg/day. Patients with chronic neutropenia: The recommended daily starting dose is 5 mcg/kg/day in idiopathic neutropenia. Peripheral blood progenitor cell collection and therapy: The recommended starting dose is 10 mcg/kg/day. Dose may be adjusted as required. HIV infection and persistent neutropenia Initial: 1 mcg/kg/day, up to 4 mcg/kg/day until neutrophil count is normalized. Maintenance: 300 mcg/day. Max: 4 mcg/kg/day. Contraindication ::

Hypersensitivity to E. coli derived proteins, Filgrastim or any component of the product. Myeloid malignancies. Not to be used within 24 hr of cytotoxic chemotherapy admin due to the sensitivity of rapidly dividing myeloid cells. Severe congenital neutropaenia (Kostman’s syndrome) with abnormal cytogenetics.

Drug Precautions ::

Filgrastim should not be administered within 24 hours before and after chemotherapy. Premalignant or malignant myeloid condition; sickle-cell disease; osteoporotic bone disease; withdraw treatment if there are signs of pulmonary infiltrates. Fluid retention or heart failure. Monitor CBC and platelet count during therapy. Monitor bone density in patients with osteoporosis (long-term treatment). Regular morphological and cytogenic bone-marrow examinations in severe congenital neutropenia. Pregnancy and lactation.

Drug Side Effects ::

Musculoskeletal pain, bone pain, hypersensitivity reactions, splenic rupture, acute respiratory distress syndrome, alveolar hemorrhage and haemoptysis, sickle cell crisis, splenic enlargement, hepatomegaly, thrombocytopaenia, anaemia, epistaxis, headache, nausea, vomiting, diarrhoea, urinary abnormalities (dysuria, proteinuria, haematuria), osteoporosis, exacerbation of rheumatoid arthritis, transient decrease in blood glucose, raised uric acid, cutaneous vasculitis, transient hypotension.Potentially Fatal: Pulmonary infiltrates leading to resp failure or acute resp distress syndrome.

Pregnancy category ::

3

Drug Mode of Action ::  

Filgrastim is a granulocyte-colony stimulating factor which binds to cell surface receptors on haemetopoietic cells thus stimulating the development of granulocytes to increase their migration and cytotoxicity.

Drug Interactions ::

Myelosuppressive antineoplastic agents. Drugs which may potentiate the release of neutrophils e.g. lithium.